Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE® smallpox vaccine

Vaccine

Volumn 33, Issue 41, 2015, Pages 5425-5431

  Troy, Jesse D ^a   Hill, Heather R ^a   Ewell, Marian G ^a   Frey, Sharon E ^b  

^a EMMES CORPORATION   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Imvamune; Meta analysis; MVA vaccine; Smallpox; Vaccines; Vaccinia virus

Indexed keywords

SMALLPOX VACCINE; VIRUS ANTIBODY;

ARTICLE; BIOLOGICAL WARFARE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SMALLPOX; VACCINATION; BLOOD; FEMALE; IMMUNITY; IMMUNOLOGY; MALE;

ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; SMALLPOX; SMALLPOX VACCINE; VACCINATION;

EID: 84941874262     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.032     Document Type: Article

References (40)

1. Nabel G.J. Designing tomorrow's vaccines. N Engl J Med 2013, 368:551-560.
2. van Panhuis W.G., Grefenstette J., Jung S.Y., Chok N.S., Cross A., Eng H., et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med 2013, 369:2152-2158.
3. Fauci A.S., Morens D.M. The perpetual challenge of infectious diseases. N Engl J Med 2012, 366:454-461.
4. Rinaudo C.D., Telford J.L., Rappuoli R., Seib K.L. Vaccinology in the genome era. J Clin Invest 2009, 119:2515-2525.
5. Fontana J.M., Alexander E., Salvatore M. Translational research in infectious disease: current paradigms and challenges ahead. Transl Res 2012, 159:430-453.
6. Poland G.A., Ovsyannikova I.G., Jacobson R.M. Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther 2008, 8:1659-1667.
7. Mentzer A.J., O'Connor D., Pollard A.J., Hill A.V. Searching for the human genetic factors standing in the way of universally effective vaccines. Philos Trans R Soc Lond Ser B: Biol Sci 2015, 370.
8. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26:3551-3555.
9. Kennedy R.B., Ovsyannikova I.G., Pankratz V.S., Vierkant R.A., Jacobson R.M., Ryan M.A., et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009, 27:3319-3323.
10. Haralambieva I.H., Ovsyannikova I.G., Kennedy R.B., Larrabee B.R., Shane Pankratz V., Poland G.A. Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals. Hum Immunol 2013, 74:1263-1266.
11. Russell P.K. Vaccines in civilian defense against bioterrorism. Emerg Infect Dis 1999, 5:531-533.
12. Shchelkunov S.N. Emergence and reemergence of smallpox: the need for development of a new generation smallpox vaccine. Vaccine 2011, 29(Suppl. 4):D49-D53.
13. Poland G.A., Grabenstein J.D., Neff J.M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005, 23:2078-2081.
14. Petersen B.W., Damon I.K., Pertowski C.A., Meaney-Delman D., Guarnizo J.T., Beigi R.H., et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm Rep 2015, 64:1-26.
15. Kennedy J.S., Greenberg R.N. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009, 8:13-24.
16. Imvanex modified vaccinia Ankara virus. London, UK: European Medicines Agency. [accessed 19.05.15]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002596/human_med_001666.jsp%26mid=WC0b01ac058001d124.
17. Products for human use. Submission #144762. Register for innovative drugs. Health Canada. [accessed 19.05.15]. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/regist/reg_innov_dr-eng.php.
18. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-W94.
19. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. w64, http://www.ncbi.nlm.nih.gov/pubmed/19622511.
20. Frey S.E., Winokur P.L., Salata R.A., El-Kamary S.S., Turley C.B., Walter E.B., et al. Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario. Vaccine 2013, 31:3025-3033.
21. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
22. Frey S.E., Winokur P.L., Hill H., Goll J.B., Chaplin P., Belshe R.B. Phase II randomized, double-blinded comparison of a single high dose (5(10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1(10(8) TCID50) in healthy vaccinia-naive individuals. Vaccine 2014, 32:2732-2739.
23. von Krempelhuber A., Vollmar J., Pokorny R., Rapp P., Wulff N., Petzold B., et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010, 28:1209-1216.
24. Mack T.M., Noble J., Thomas D.B. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972, 21:214-218.
25. Sarkar J.K., Mitra A.C., Mukherjee M.K. The minimum protective level of antibodies in smallpox. Bull World Health Organ 1975, 52:307-311.
26. Taub D.D., Ershler W.B., Janowski M., Artz A., Key M.L., McKelvey J., et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008, 121:1058-1064.
27. Kim S.H., Yeo S.G., Park K.H., Bang J.W., Kim H.B., Kim N.J., et al. The persistence of humoral and cellular immunities more than three decades after smallpox vaccination. Clin Microbiol Infect 2007, 13:91-93.
28. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
29. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171:4969-4973.
30. el-Ad B., Roth Y., Winder A., Tochner Z., Lublin-Tennenbaum T., Katz E., et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990, 161:446-448.
31. Gallwitz S., Schutzbank T., Heberling R.L., Kalter S.S., Galpin J.E. Smallpox: residual antibody after vaccination. J Clin Microbiol 2003, 41:4068-4070.
32. Hatakeyama S., Moriya K., Saijo M., Morisawa Y., Kurane I., Koike K., et al. Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations. Clin Diagn Lab Immunol 2005, 12:520-524.
33. Putz M.M., Alberini I., Midgley C.M., Manini I., Montomoli E., Smith G.L. Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol 2005, 86:2955-2960.
34. Toft L., Storgaard M., Muller M., Sehr P., Bonde J., Tolstrup M., et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 2014, 209:1165-1173.
35. Klein S.L., Marriott I., Fish E.N. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg 2015, 109:9-15.
36. Klein S.L., Jedlicka A., Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010, 10:338-349.
37. Lu F.X., Abel K., Ma Z., Rourke T., Lu D., Torten J., et al. The strength of B cell immunity in female rhesus macaques is controlled by CD8+ T cells under the influence of ovarian steroid hormones. Clin Exp Immunol 2002, 128:10-20.
38. Klein S.L., Poland G.A. Personalized vaccinology: one size and dose might not fit both sexes. Vaccine 2013, 31:2599-2600.
39. Pennell L.M., Galligan C.L., Fish E.N. Sex affects immunity. J Autoimmun 2012, 38:J282-J291.
40. Walsh S.R., Wilck M.B., Dominguez D.J., Zablowsky E., Bajimaya S., Gagne L.S., et al. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 2013, 207:1888-1897.